SPRING PHARMACEUTICAL GROUP, INC.: 10-Q filed 2016-08-15
What SPRING PHARMACEUTICAL GROUP, INC. reported in its quarterly report filed 2016-08-15 (fiscal Q1 2017): 29 published measures, 59 facts as tagged in accession 0001096906-16-001828.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-08-15
- Fiscal period
- fiscal Q1 2017
- Accession
- 0001096906-16-001828 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All SPRING PHARMACEUTICAL GROUP, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 81,130,782 | USD | |
| At 2016-03-31 | 81,315,507 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 79,951,533 | USD | |
| At 2016-03-31 | 80,349,551 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 9,006,665 | USD | |
| At 2016-03-31 | 7,639,084 | USD | |
| At 2015-06-30 | 13,442,340 | USD | |
| At 2015-03-31 | 13,083,532 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 1,575,535 | USD | 91 |
| 2015-04-01 to 2015-06-30 | 3,004,445 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 2,701,721 | USD | 91 |
| 2015-04-01 to 2015-06-30 | 1,827,942 | USD | 91 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 639,877 | USD | 91 |
| 2015-04-01 to 2015-06-30 | 409,806 | USD | 91 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -1,114,485 | USD | 91 |
| 2015-04-01 to 2015-06-30 | -1,530,666 | USD | 91 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -572,724 | USD | 91 |
| 2015-04-01 to 2015-06-30 | -976,705 | USD | 91 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 12,999,381 | USD | |
| At 2016-03-31 | 12,872,997 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 2,132,837 | USD | 91 |
| 2015-04-01 to 2015-06-30 | 3,968,295 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 12,616,914 | USD | |
| At 2016-03-31 | 11,421,267 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 1,179,249 | USD | |
| At 2016-03-31 | 965,956 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 432,048 | USD | |
| At 2016-03-31 | 533,262 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 1,667,397 | USD | 91 |
| 2015-04-01 to 2015-06-30 | 1,714,481 | USD | 91 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 2,241,244 | USD | |
| At 2016-03-31 | 2,287,312 | USD |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 3,800,234 | USD | 91 |
| 2015-04-01 to 2015-06-30 | 5,682,776 | USD | 91 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 69,160 | USD | 91 |
| 2015-04-01 to 2015-06-30 | 190,568 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 29,764,168 | shares | |
| At 2016-03-31 | 29,720,690 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | -1,248,124 | USD | |
| At 2016-03-31 | 837,064 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 16,288,984 | USD | |
| At 2016-03-31 | 16,070,702 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | -3,289,603 | USD | |
| At 2016-03-31 | -3,197,705 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-06-30 | 11,701,216 | USD | |
| At 2016-03-31 | 12,295,147 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -509,653 | USD | 91 |
| 2015-04-01 to 2015-06-30 | 3,360,510 | USD | 91 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 850,357 | USD | 91 |
| 2015-04-01 to 2015-06-30 | 754,068 | USD | 91 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 176,525 | USD | 91 |
| 2015-04-01 to 2015-06-30 | 153,219 | USD | 91 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -282,974 | USD | 91 |
| 2015-04-01 to 2015-06-30 | -336,462 | USD | 91 |
Deferred income tax expense or benefit
The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -18,630 | USD | 91 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | 88,876 | USD | 91 |
| 2015-04-01 to 2015-06-30 | -75,125 | USD | 91 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-06-30 | -12,762 | USD | 91 |
| 2015-04-01 to 2015-06-30 | -1,421,332 | USD | 91 |
Inspect the source
- Entity
- SPRING PHARMACEUTICAL GROUP, INC. / CIK 0000847464
- Captured
- SEC response SHA-256
21fd63bfa4a441f5dd22dbcc8093e88a40c5d63950c8b6833c77a7b4245f4dc7
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000847464.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))